PYXSPyxis Oncology, Inc.

PYXS Stock Price, Valuation & Chart | Pyxis Oncology, Inc.

Compare

$3.750+0.31 (+9.01%)

At close · 02 Sept 2026, 08:00 pm

Sector: Healthcare Industry: Biotechnology PYXS intrinsic value PYXS calculated fair value vs price

Overview Financials Dividends Ratios

PYXS Historical price chart

PYXS Key Stats

Fair Value

Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock

Market Capitalization237.58M

PE Ratio-2.66

EPS-1.41

Trading Volume722.71K

Today's High/Low3.77/3.45

Dividend Yield0.00

52 Week High/Low5.55/1.03

Shares Outstanding63.36M

PYXS Financial Statement

PYXS Analyst ratings

PYXS Analysis & performance metrics

PYXS Company profile

Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include…

Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and…

PYXS Management team

Name

Position

Michael Bui

Head of Global Regulatory Affairs

Supriya Roth Ph.D.

Head of Commercial Development

Lara S. Sullivan M.D., MBACEO

Chief Executive Officer, President, Chief Medical Officer & Director

Pamela Yanchik Connealy M.B.A.CFO

Chief Financial Officer & Chief Operating Officer

Jitendra Wadhane C.A., CPA

Chief Accounting Officer, Senior Vice President of Finance & Corporate Controller

Balu N. Balasubramanian Ph.D.CTO

Interim Chief Technology Officer

Jan Pinkas Ph.D.

Chief Scientific Officer

Charles T. Gombar Ph.D.

Senior Vice President of Portfolio & Program Management

Name

Position

Michael Bui

Head of Global Regulatory Affairs

Supriya Roth Ph.D.

Head of Commercial Development

Lara S. Sullivan M.D., MBACEO

Chief Executive Officer, President, Chief Medical Officer & Director

Pamela Yanchik Connealy M.B.A.CFO

Chief Financial Officer & Chief Operating Officer

Jitendra Wadhane C.A., CPA

Chief Accounting Officer, Senior Vice President of Finance & Corporate Controller

Balu N. Balasubramanian Ph.D.CTO

Interim Chief Technology Officer

Jan Pinkas Ph.D.

Chief Scientific Officer

Charles T. Gombar Ph.D.

Senior Vice President of Portfolio & Program Management

Management Team

Michael Bui

Head of Global Regulatory Affairs

Supriya Roth Ph.D.

Head of Commercial Development

Lara S. Sullivan M.D., MBACEO

Chief Executive Officer, President, Chief Medical Officer & Director

Pamela Yanchik Connealy M.B.A.CFO

Chief Financial Officer & Chief Operating Officer

Jitendra Wadhane C.A., CPA

Chief Accounting Officer, Senior Vice President of Finance & Corporate Controller

Balu N. Balasubramanian Ph.D.CTO

Interim Chief Technology Officer

Jan Pinkas Ph.D.

Chief Scientific Officer

Charles T. Gombar Ph.D.

Senior Vice President of Portfolio & Program Management

Management

Michael Bui

Head of Global Regulatory Affairs

Supriya Roth Ph.D.

Head of Commercial Development

Lara S. Sullivan M.D., MBACEO

Chief Executive Officer, President, Chief Medical Officer & Director

Pamela Yanchik Connealy M.B.A.CFO

Chief Financial Officer & Chief Operating Officer

Jitendra Wadhane C.A., CPA

Chief Accounting Officer, Senior Vice President of Finance & Corporate Controller

Balu N. Balasubramanian Ph.D.CTO

Interim Chief Technology Officer

Jan Pinkas Ph.D.

Chief Scientific Officer

Charles T. Gombar Ph.D.

Senior Vice President of Portfolio & Program Management

Total 8 executives

PYXS Frequently asked questions

What is Pyxis Oncology, Inc. (PYXS) Stock Price?

Current stock price of Pyxis Oncology, Inc. (PYXS) stock is $3.750. The stock price is +9.01% higher in the session. The intraday range can be seen from this page. Volume of Pyxis Oncology, Inc. (PYXS) stock is 722.71K.

Last updated at 02 Sept 2026, 08:00 pm.

Why is the Pyxis Oncology, Inc. (PYXS) stock price going up or down today?

The stock price of Pyxis Oncology, Inc. (PYXS) can change with earnings, company news, and overall market sentiment. Pyxis Oncology, Inc. operates in the Healthcare / Biotechnology market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the Pyxis Oncology, Inc. stock expensive at its current price?

Whether Pyxis Oncology, Inc. looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for PYXS on this page is -2.66. EPS on this page is -1.41. Compare those figures with peers and growth expectations before deciding if the current Pyxis Oncology, Inc. price is justified.

How has the stock price of Pyxis Oncology, Inc. (PYXS) performed historically?

Historical performance for Pyxis Oncology, Inc. (PYXS) is shown on the price chart on this page. Review multi-period moves alongside volume to see how PYXS reacted to past earnings and market events.

Should I buy Pyxis Oncology, Inc. (PYXS) stock, at this price?

Buying Pyxis Oncology, Inc. (PYXS) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.